CO-VANTAGE-DATA-CENTERS
10.1.2023 14:01:55 CET | Business Wire | Press release
Vantage Data Centers, a leading global provider of hyperscale data center campuses, today announced its entrance into London with the development of a 48MW £500 million campus. In addition, the company has opened a second 40MW data center on its existing Cardiff campus.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230110005323/en/
Vantage Data Centers’ LHR1 campus will include 48MW of IT capacity across two facilities. (Photo: Business Wire)
Situated on nearly five acres (two hectares) in the PowerGate neighborhood of North Acton, an established data center community in the northwest part of the city, Vantage’s London campus will total 430,000 square feet (40,000 square meters) across two 24MW multi-story data centers once fully developed. The first facility will open its doors to hyperscale customers and cloud providers in late 2024, which will mark Vantage’s 11th campus in EMEA.
“Vantage has experienced rapid growth over the past three years as we continue developing state-of-the-art data center campuses across EMEA,” said Antoine Boniface, president, EMEA at Vantage Data Centers. “With London being one of the largest data center markets in the world, this expansion further solidifies Vantage’s role at the forefront of the digital infrastructure revolution. With relatively little inventory available in London and requirements on the rise, we are ideally positioned to deliver for our customers.”
London is the largest of the FLAP (Frankfurt, London, Amsterdam and Paris) data center markets, buoyed by the U.K.’s leadership in public cloud infrastructure adoption. Findings from Structure Research indicate that hyperscale data center offerings currently account for 48% of the London market, which is projected to grow to 66% by 2027, making this a key time for Vantage to enter the arena.
“The continuing demand for data centers in London offers a prime opportunity for Vantage Data Centers to make its entrance into the highly-coveted market,” said Tim Kay, deputy director for technology, Department for International Trade in London. “Vantage’s presence in London will play a key role in enabling leading technology enterprises with additional IT capacity to support digital transformation initiatives and cloud adoption.”
In addition to the development of its London campus, Vantage has completed the first phase (12MW) of a second 40MW facility at its growing Cardiff campus, located in Wales, the second largest data center market in the U.K. The new facility boasts one of the lowest power usage effectiveness (PUE) ratios across all of Vantage’s facilities thanks in part to its extremely energy efficient indirect evaporative free cooling system, which negates the need for compressors in the cooling cycle.
Once fully developed, the 46-acre campus (19 hectares) will include three data centers totaling 148MW across 2 million square feet (186,000 square meters). Conveniently located in the U.K.’s tech corridor near the M4 and just 100 miles (160 kilometers) from London’s urban density, the campus offers numerous connectivity options with low latency between Wales and London of less than 1.5 milliseconds. The sustainable campus operates entirely on renewable energy sources.
“We are delighted to welcome customers to our newest data center in Cardiff,” said Justin Jenkins, Vantage’s chief operating officer, Europe and president, U.K. “The significant investment Vantage is making in Wales is transforming the area into one of Europe’s leading data center hubs and a top cloud region in the U.K. This is great news for the local economy as the added capacity will attract more global companies to the region, ensuring additional work for hundreds of local contractors on site and creating new permanent job opportunities.”
In December 2021, Vantage opened a corporate office in the Farringdon district of Central London to support the company’s scaling operations across EMEA.
About Vantage Data Centers
Vantage Data Centers powers, cools, protects and connects the technology of the world’s well-known hyperscalers, cloud providers and large enterprises. Developing and operating across five continents in North America, EMEA and Asia Pacific, Vantage has evolved data center design in innovative ways to deliver dramatic gains in reliability, efficiency and sustainability in flexible environments that can scale as quickly as the market demands.
For more information, visit http://www.vantage-dc.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230110005323/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Philip Morris International and Maestro Andrea Bocelli Present “Believe. Further”29.6.2026 12:00:00 CEST | Press release
A new platform for dialogue on progress, reflecting a mutual commitment to advancing positive change Philip Morris International (PMI) (NYSE: PM) and Maestro Andrea Bocelli today presented “Believe. Further”, a multi-year platform designed to engage audiences in a broader conversation on progress and positive change. The launch took place at the Torre dell’Arsenale in Venice, where heritage and forward movement meet, a fitting setting for two voices on a similar path. What do you do when the world has already decided what you are? “Believe. Further” begins from that question. It is built around a shared belief in progress and a shared conviction in transformation. At a time when science and technology allow better choices, it brings together two voices that, independently and in parallel, are undergoing a change in motion, and invites the beginning of a different conversation with society at large. Maestro Bocelli’s journey has been defined by belief. From the beginnings of his career
Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release
Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
